Other News

MERIT MEDICAL RECEIVES 510(K) APPROVAL FOR EMBOCUBE EMBOLIZATION GELATIN FOR EMBOLIZATION OF HYPERVASCULAR TUMORS

SOUTH JORDAN, Utah – November 29, 2018 – Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in interventional, diagnostic and therapeutic procedures, announces that it has received 510(k) clearance for EmboCube Embolization Gelatin. EmboCube is indicated for use in embolization of hypervascular tumors. The […]

Reprieve Cardiovascular introduces guided diuretic therapy at major heart failure congresses

MILFORD, Massachusetts – ( BUSINESS WIRE ) – Reprieve Cardiovascular ™, a pioneering medical device company focused on improving the treatment of patients with acute decompensated heart failure (ADHF), will soon be at various well-known sites Conferences for Heart Failure represented. Reprieve-guided diuretic therapy will be the subject of the two presentations […]

Amarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference

BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 28, 2018 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin’s president and chief executive officer, is scheduled to participate in a fireside chat regarding […]

InspireMD Announces Positive Long-Term Safety and Efficacy Data from Ongoing CGuard™ EPS Registries at the Recent 45th Annual Symposium on Vascular and Endovascular Issues, Techniques, Horizons (VEITHsymposium)

TEL AVIV, Israel, Nov. 29, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced details from several presentations of updated CGuard™ EPS data at the recent VEITHsymposium […]

First Patient Treated In Biosense Webster U.S. IDE Study Evaluating Next Generation Balloon Ablation Catheter For Atrial Fibrillation

IRVINE, Calif., Nov. 29, 2018 /PRNewswire/ — Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has enrolled and treated the first patient in its STELLAR** U.S. Investigational Device Exemption (IDE) study. The study will evaluate the safety […]

CardioFocus Completes Enrollment In HeartLight® X3 Trial

MARLBOROUGH, Mass., Nov. 29, 2018 /PRNewswire/ — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced completed enrollment in a trial to evaluate its next-generation HeartLight® X3 Endoscopic Ablation System. A total of 60 patients have been treated in this pivotal confirmatory trial with a one-month […]

Adagio Medical’s Persistent Atrial Fibrillation Cryoablation Study Demonstrates Early Single-Treatment Results Superior To Ablation Devices Requiring Two Procedures

LAGUNA HILLS, Calif., Nov. 28, 2018 /PRNewswire/ — Adagio Medical, Inc., developer of the iCLAS™ technology, the company’s ultra-low temperature intelligent continuous lesion ablation system for the treatment of cardiac arrhythmias, announces updates to its ongoing cryoablation study for Persistent Atrial Fibrillation (PsAF). The study is currently being conducted at two clinical sites […]

Canon Medical’s Ultrasound Detail and Industry-Leading Depth Make It Easier for Clinicians to Image a Wide Range of Patients

CHICAGO–(BUSINESS WIRE)–Canon Medical Systems USA, Inc. is showcasing its premium Aplio™ i-series ultrasound platform with the deepest penetration available on the market at this year’s Radiological Society of North America (RSNA) annual meeting in Chicago, November 25 – 30, 2018 (Booth #1938, South Level 3). The Aplio i-series platform, a highly advanced and scalable […]

Resverlogix Announces Publication on Apabetalone in Atherosclerosis Journal

CALGARY, Alberta, Nov. 28, 2018 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an article titled: “Apabetalone downregulates factors and pathways associated with vascular calcification” in Atherosclerosis, the official peer-reviewed scientific journal of the European Atherosclerosis Society. “Apabetalone and its unique mechanism […]

InspireMD Announces Regulatory and Reimbursement Approval of CGuard™ Embolic Prevention System in Australia

TEL AVIV, Israel, Nov. 28, 2018 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that its novel CGuard™ Embolic Prevention System (EPS) has been granted regulatory approval […]